TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Akebia Therapeutics ( (AKBA) ).
On November 12, 2025, Akebia Therapeutics and MEDICE Arzneimittel Putter GmbH & Co. KG amended their existing license agreement, allowing MEDICE to manufacture Vafseo tablets for treating anemia in chronic kidney disease patients in Europe and certain other regions. This amendment includes Akebia supplying the drug substance vadadustat and retaining ownership of any intellectual property arising from the manufacturing process, potentially strengthening Akebia’s market position and operational capabilities in the nephrology sector.
The most recent analyst rating on (AKBA) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Akebia Therapeutics stock, see the AKBA Stock Forecast page.
Spark’s Take on AKBA Stock
According to Spark, TipRanks’ AI Analyst, AKBA is a Neutral.
Akebia Therapeutics faces significant financial challenges, including declining revenue and high leverage. However, the strong launch of Vafseo and strategic market expansion provide some optimism. Despite these positive developments, the stock remains a risk due to ongoing financial instability and valuation challenges.
To see Spark’s full report on AKBA stock, click here.
More about Akebia Therapeutics
Akebia Therapeutics is a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, particularly targeting anemia associated with chronic kidney disease.
Average Trading Volume: 4,276,659
Technical Sentiment Signal: Sell
Current Market Cap: $443.2M
For an in-depth examination of AKBA stock, go to TipRanks’ Overview page.